ZYDELIG is a PI3K delta inhibitor.
This means ZYDELIG targets PI3K delta,
one of the proteins responsible for lymphoma and other cell growth.
ZYDELIG is the first of a new class of drug for patients with
returning or relapsed FL who have received
at least 2 prior medicines.
ZYDELIG helps stop the growth of your cancer cells
ZYDELIG blocks a signal that helps
lymphoma and normal cells grow and survive.
For many patients, blocking this signal can help slow the cancer.
Unlike chemotherapy, ZYDELIG initially causes the lymphoma blood
cell count to go up as the lymph nodes and other components of FL go down.
In most patients, this is followed by a decline in the lymphoma blood cells over time.
Adding ZYDELIG has been proven effective
In a clinical trial of 72 patients with relapsed FL,
54% responded to treatment with ZYDELIG,
with 8% experiencing remission and 46% experiencing a
Your Partner in TherapyZYDELIG
Designed to help you access,
afford, and adhere to
What is the most important information I should know about ZYDELIG?
ZYDELIG can cause serious side effects that can lead to death, including:
Liver problems. Abnormal liver blood test results are common during treatment with ZYDELIG. ZYDELIG can cause severe liver problems. Your doctor will do blood tests before and during your treatment with ZYDELIG to check for liver problems. Tell your doctor right away if you get yellowing of your skin or the white part of your eyes (jaundice), dark or brown (tea-colored) urine, pain in the upper right side of your stomach area (abdomen), or bleeding or bruising more easily than normal.